LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

4.52 -0.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.48

Максимум

4.54

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	14M 35M
Предишно отваряне	4.96
Предишно затваряне	4.52

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19.02.2026 г., 23:39 ч. UTC

Придобивния, сливания и поглъщания

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19.02.2026 г., 23:38 ч. UTC

Печалби

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19.02.2026 г., 23:38 ч. UTC

Печалби

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19.02.2026 г., 23:38 ч. UTC

Печалби

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19.02.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19.02.2026 г., 23:34 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19.02.2026 г., 23:34 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19.02.2026 г., 23:33 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19.02.2026 г., 23:33 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19.02.2026 г., 22:13 ч. UTC

Пазарно говорене

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19.02.2026 г., 22:08 ч. UTC

Печалби

Fairfax Financial 4Q Rev $8.11B >FFH.T

19.02.2026 г., 22:07 ч. UTC

Печалби

Eldorado Gold 4Q EPS $1.19 >ELD.T

19.02.2026 г., 22:06 ч. UTC

Печалби

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19.02.2026 г., 22:05 ч. UTC

Печалби

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19.02.2026 г., 22:05 ч. UTC

Печалби

Eldorado Gold 4Q Rev $577.2M >ELD.T

19.02.2026 г., 22:04 ч. UTC

Печалби

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19.02.2026 г., 22:04 ч. UTC

Печалби

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

19.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

19.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

19.02.2026 г., 21:43 ч. UTC

Печалби

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19.02.2026 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19.02.2026 г., 21:42 ч. UTC

Печалби

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19.02.2026 г., 21:41 ч. UTC

Печалби

Correct: St Barbara 1H Net Loss A$249,000

19.02.2026 г., 21:40 ч. UTC

Печалби

St Barbara 1H Net Loss A$249 Million

19.02.2026 г., 21:39 ч. UTC

Печалби

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19.02.2026 г., 21:37 ч. UTC

Печалби

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19.02.2026 г., 21:37 ч. UTC

Печалби

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.